(Reuters) -Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 ...

Investors reacted positively to the news, as the FDA’s approval not only enhances Novavax’s product offering but also solidifies its partnership with Sanofi, a key player in the vaccine market. The ...

Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics ...

Novavax shares jumped 16.6% to $7.84 in the pre-market trading session. Here are some other stocks moving in pre-market ...

After a prolonged wait, American company Novavax (Nasdaq: NVAX) has received full approval from the US regulator for its ...

Brazil is no longer allowed to export poultry and meat products to the European Union due to the outbreak of bird flu, the ...

The latest investor updates on stocks that are trending on Monday.

The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to ...

The U.S. Food and Drug Administration approved Novavax’s COVID-19 vaccine, but limited its use to older adults and people over the age of 12 with conditions ...

JN.1, a variant of Omicron BA.2.86, emerged in late 2023 with 30 immune-evasion mutations. It spreads more efficiently due to ...

Gaithersburg’s Novavax has secured formal regulatory approval for its Covid vaccine. It's a major win, after the FDA delayed ...

The US Food and Drug Administration approved Novavax's COVID-19 vaccine, but limited its use to older adults and people over ...